Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 130 participants.

Also called NCT03206060

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 130 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03206060
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT03206060. Allocation not applicable; no masking; primary purpose treatment. Start 2017-10-10 (actual); primary completion 2030-01-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
Condition
Pheochromocytoma
Condition
Paraganglioma
Condition
Neuroendocrine Tumors
Condition
Neuroendocrine Neoplasms
Intervention (Drug)
Lu-177-DOTATATE
Intervention (Drug)
Ga-68-DOTATATE
Lead sponsor
National Cancer Institute (NCI) (class: US National Institutes of Health)

Record details

Record id
cardio:ct-nct03206060
Content hash
88bd5730328a10dbbce9c99a01adb09d1d5cac623104734b971018c4d9d01bed